Journal
BMC CANCER
Volume 22, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12885-022-09441-3
Keywords
Cytotoxic chemotherapy; Platinum-based chemotherapy; Second-line setting; Single-agent chemotherapy; Survival
Categories
Funding
- Japan Society for Respiratory Endoscopy
- Japanese Association for Thoracic Surgery
- Japanese Association for Chest Surgery
- Japanese Respiratory Society
- Japan Lung Cancer Society
Ask authors/readers for more resources
This study evaluated the efficacy of platinum-doublet chemotherapy as a second-line treatment for patients with unresectable stage III NSCLC following platinum-based chemoradiotherapy. The results showed that platinum-doublet chemotherapy significantly improved overall survival and may be a promising treatment for these patients.
Background: Platinum-based chemoradiotherapy is the standard treatment for unresectable stage III non-small-cell lung cancer (NSCLC). However, few studies have evaluated the efficacy of subsequent chemotherapy for relapsed NSCLC following platinum-based chemoradiotherapy. This study aimed to evaluate the efficacy of platinum-doublet chemotherapy as a second-line treatment for patients with unresectable stage III NSCLC. Methods: We retrospectively evaluated patients with unresectable stage III NSCLC treated with cytotoxic chemotherapy following platinum-based chemoradiotherapy who were registered in a nationwide registry NSCLC database. Patients were divided into the platinum-doublet chemotherapy (platinum) group and single-agent chemotherapy (non-platinum) group based on the type of second-line chemotherapy. Results: The platinum group (n = 119) showed significantly better overall survival (OS) than the non-platinum group (n = 201) (median OS: 21.5 vs. 10.5 months, hazard ratio [HR]: 0.54, 95% confidence interval [CI]: 0.40-0.73, p < 0.001). OS from the beginning of chemoradiotherapy was also significantly better in the platinum group than in the non-platinum group (median OS: 34.9 vs. 21.8 months, HR: 0.58, 95% CI: 0.43-0.79, p = 0.001). In the multivariate analysis, platinum-doublet chemotherapy as second-line therapy, female sex, clinical stage IIIA, and duration of >= 8.6 months from the beginning of first-line therapy to the beginning of second-line therapy were associated with significantly better OS. Conclusion: Platinum-doublet chemotherapy as a second-line therapy may prolong survival in unresectable stage III NSCLC patients following platinum-based chemoradiotherapy. Thus, re-administration of platinum agents may be a promising treatment for unresectable stage III NSCLC treated with platinum-based chemoradiotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available